Published in Law and Health Weekly, July 22nd, 2006
The SPA agreement with the FDA concerns the suitability of the trial design to support regulatory approval.
The randomized, double-blind, two-arm registrational clinical trial is expected to commence shortly. The trial is expected to enroll approximately 500 patients with previously untreated stage III or stage IV metastatic melanoma. Patients will...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.